Clinical Data Initiates Long-Term Safety Study For Vilazodone

Clinical Data, Inc. (NASDAQ: CLDA), a leader in the development of targeted therapeutics and predictive tests from a growing portfolio of proprietary genetic biomarkers, announced that it has initiated a long-term safety study for Vilazodone, the company’s drug candidate for the treatment of depression, ahead of schedule. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 20th, 2007